APA 6th Edition Badžek, S., Curić, Z., Krajina, Z., Pleština, S., Golubić-Ćepulić, B. i Radman, I. (2008). Treatment of Cancer-Related Anemia. Collegium antropologicum, 32 (2), 615-622. Preuzeto s https://hrcak.srce.hr/27205
MLA 8th Edition Badžek, Saša, et al. "Treatment of Cancer-Related Anemia." Collegium antropologicum, vol. 32, br. 2, 2008, str. 615-622. https://hrcak.srce.hr/27205. Citirano 18.11.2019.
Chicago 17th Edition Badžek, Saša, Zvonimir Curić, Zdenko Krajina, Stjepko Pleština, Branka Golubić-Ćepulić i Ivo Radman. "Treatment of Cancer-Related Anemia." Collegium antropologicum 32, br. 2 (2008): 615-622. https://hrcak.srce.hr/27205
Harvard Badžek, S., et al. (2008). 'Treatment of Cancer-Related Anemia', Collegium antropologicum, 32(2), str. 615-622. Preuzeto s: https://hrcak.srce.hr/27205 (Datum pristupa: 18.11.2019.)
Vancouver Badžek S, Curić Z, Krajina Z, Pleština S, Golubić-Ćepulić B, Radman I. Treatment of Cancer-Related Anemia. Collegium antropologicum [Internet]. 2008 [pristupljeno 18.11.2019.];32(2):615-622. Dostupno na: https://hrcak.srce.hr/27205
IEEE S. Badžek, Z. Curić, Z. Krajina, S. Pleština, B. Golubić-Ćepulić i I. Radman, "Treatment of Cancer-Related Anemia", Collegium antropologicum, vol.32, br. 2, str. 615-622, 2008. [Online]. Dostupno na: https://hrcak.srce.hr/27205. [Citirano: 18.11.2019.]
Sažetak Anemia with consequent tissue hypoxia is common problem in cancer patients. Developed via various patophysiological
mechanisms, it has deleterious effect on quality of life and survival of patients with cancer. Recognition of symptoms
and timely initiation of treatment improve patients’ quality of life, as well as efficacy of oncological treatment. Red blood
cells transfusions are well known and efficient way of anemia correction. They are »golden standard« in treatment of
cancer-related anemia today, and are unavoidable in almost all patients with hemoglobin concentration below 80 g/L.
Newest therapy guidelines in developed countries, supported by recent literature, encourage use of recombinant human
erythropoietin (rHu-EPO), although detailed meta-analyses and prospective randomized clinical trials have shown that
rHu-EPO decreases the need for transfusions in only 9–45% patients with cancer, only if they have mild anemia. rHu-EPO
increases incidence of thromboembolic events, and suspicion arises that it supports tumor cells growth and multiplication.
Therefore, it is necessary to define subgroups of patients which are best candidates for rHu-EPO therapy, to accomplish
lower intensity of transfusion therapy.